[EN] GOLD (I)-PHOSPHINE 1,2,3-TRIAZOLE DERIVATIVES WITH ANTIOBIOTIC PROPERTIES<br/>[FR] DÉRIVÉS D'OR (I)-PHOSPHINE 1,2,3-TRIAZOLE PRÉSENTANT DES PROPRIÉTÉS ANTIBIOTIQUES
申请人:UNIV STRASBOURG
公开号:WO2019243273A1
公开(公告)日:2019-12-26
The present invention relates to gold (l)-phosphine 1,2,3-triazole compounds, and their use in a human or animal medicine. The present invention also relates to using such compounds for the prevention and/or treatment of an infection, i.e. inhibitors of growth of Gram-positive and/or Gram-negative bacteria. On another aspect the invention relates to the synthesis of the gold (l)-phosphine compounds of the invention and to their synthesis intermediates. The present invention finds applications in the medical, veterinary and/or chemical fields.
The invention relates to a compound of formula (I)
wherein R
1
to R
4
are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
New Chiral Zwitterionic Phosphorus Heterocycles: Synthesis, Structure, Properties and Application as Chiral Solvating Agents
作者:Andrey E. Sheshenev、Ekaterina V. Boltukhina、Anastasiya A. Grishina、Ivana Cisařova、Ilya M. Lyapkalo、King Kuok Mimi Hii
DOI:10.1002/chem.201300062
日期:2013.6.17
A family of new chiral zwitterionic phosphorus‐containing heterocycles (zPHC) have been derived from methylene‐bridged bis(imidazolines). These structures were unambiguously determined, including single‐crystal XRD analysis for two compounds. The stability, acid/base and electronic properties of these dipolar phosphorusheterocycles were subsequently investigated. zPHCs can be successfully employed
Pyridine derivatives as agonists of the CB2 receptor
申请人:Bissantz Caterina
公开号:US09290451B2
公开(公告)日:2016-03-22
The invention relates to a compound of formula (I)
Wherein R1, R2, R3 and R4 are defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases.
A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.